JY
CTKB icon

Jeff Yass’s Cytek Biosciences CTKB Stock Holding History

Jeff Yass’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-31,200
Closed -$209K – 12182
2024
Q1 		$209K Buy
31,200
+14,500
+87% +$115K ﹤0.01% 10508
2023
Q4 		$152K Buy
+16,700
New +$105K ﹤0.01% 10965

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jeff Yass's CTKB Position: Q2 2026 in Review

Jeff Yass increased its Cytek Biosciences (CTKB) stake by 1,117% in Q2 2026, buying an estimated $2.67M and bringing the position to 681,705 shares worth $3.02M. The position accounts for ﹤0.01% of the portfolio, ranked #5600.

Jeff Yass first reported a position in CTKB in Q1 2022 and has held it in 15 quarters since. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Jeff Yass held 681,705 shares of Cytek Biosciences worth $3.02M as of Q2 2026.
  • Jeff Yass bought 625,695 Cytek Biosciences shares in Q2 2026, an estimated $2.67M.
  • Cytek Biosciences made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5600 holding.
  • Jeff Yass first reported a position in Cytek Biosciences in Q1 2022 and has held it in 15 quarters since.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.